The IMIV lab (UMR1023 Inserm/CEA/Paris Sud University and ERL 9218 CNRS) created on 1st January 2015 is a pluridisciplinary research lab dedicated to In Vivo Molecular Imaging..

The main objectives of IMIV are

• To develop new molecular probes, new imaging protocols, and new methodological approaches for in vivo molecular imaging.
• To use these new methods to elucidate molecular mechanisms underlying disease onset and evolution so as to ultimately improve patient management.

Our goal is to perform original proofs of concept in in vivo molecular imaging, validate them in small patient cohorts and then disseminate these methods in France and abroad. 

To reach these goals, our plan is as follows

First, to contribute to significant advances in each of the specialties involved in molecular imaging, namely:

• The design and characterization of the imaging agents. The development of new imaging protocols and associated quantification methods.
• The investigation of animal models to validate new concepts in molecular imaging and understand the molecular mechanisms behind a number of diseases.
• The design of clinical research protocols to demonstrate the role molecular imaging can play to characterize pathophysiological processes and to improve patient care.

Then, based on these four pillars central to our research, we address specific projects related to molecular imaging and requiring the broad range of expertise gathered in the lab. At the moment, we are involved in three highly innovative transversal projects: neuroinflammation imaging as a ubiquitous process in a number of disease, simultaneous PET-MR imaging, and the LOTUS project aiming at considerably facilitating the production and use of new radiopharmaceutical use for safe and fast evaluation of their clinical value.